June 2025: Key Moves in MedTech & Life Sciences

June 2025: Key Moves in MedTech & Life Sciences

Following a dynamic start to the year, the momentum across the Medical & Life Sciences space hasn’t slowed down. June brought another wave of headline-making acquisitions, regulatory milestones, and innovative collaborations that continue to redefine the industry.

As recruiters deeply engaged in this ever-evolving field, we remain tuned in to the developments shaping the future of healthcare, from biotech breakthroughs to strategic realignments across major players.

Here’s a recap of some of the key highlights from June:

• Eli Lilly and Company announced their agreement to acquire Verve Therapeutics, a Massachusetts-based clinical-stage biotech developing genetic medicines for cardiovascular diseases. The total equity value is approximately $1.3 billion
  
• BioNTech announced the agreement to acquire all of the shares of CureVac,  a clinical-stage biotech developing transformative medicines in oncology and infectious diseases based on mRNA. 
• Illumina announced they had agreed with Standard BioTools by which they will acquire SomaLogic, a leading data-driven proteomics business, for $350 million, with $75 million in near-term performance-based milestones
• Medical Manufacturing Technologies, a global provider of automated medical device manufacturing solutions, acquired Comco, a leader in micro precision sandblasting, to enhance its abrasive technology offerings.
• Verge Medical, the privately held MedTech company focused on vascular care, announced the acquisition of the RoVo™ System and its Temporary Occlusion Embolectomy technology from 2MG Medical.
• atai Life Sciences, the clinical-stage biopharma focused on mental health treatments, and Beckly Psytech, announced an agreement to merge under an all-share transaction agreement, subject to Phase IIb success criteria
• RayzeBio, a subsidiary of Bristol Myers Squibb, announced it will license a therapeutic and diagnostic asset for prostate cancer from Philochem, with $350 million up front and an additional $1 billion in development, regulatory and commercial milestones
• Calico Life Sciences, an Alphabet biotech company focused on age-related diseases and ageing, signed an exclusive agreement with Mabwell Bioscience for the development & commercialisation of interleukin-11 targeting therapeutics. The deal includes an upfront payment of $25 million with a possible addition of $571 million tied to milestones.
• GI Windows received FDA 510(k) clearance for its Flexagon self-forming magnet technology, a laparoscopic and endoscopic delivery system
• Curiteva announced FDA 510(k) clearance for the Inspire Trabecular PEEK Standalone ALIF system, the first-ever 3D printed PEEK standalone implant
• EXO landed FDA clearance for 2 AI lung ultrasound apps on Exo Iris
• Stryker received FDA 510(k) clearance for InCompass Total Ankle

As we move into the second half of the year, we’ll continue monitoring the trends and breakthroughs that are setting the pace for what's next. Stay tuned for our July edition, where we’ll bring you the latest updates driving transformation across Biotech, MedTech, and Life Sciences.

If you're navigating growth or building out your team in this fast-paced space, our specialist recruiters are here to help.